OAB and Incontinence

On the urinary side, Fosnight prioritizes pelvic floor physical therapy as a first-line intervention for incontinence, citing evidence of significant symptom improvement.

A recap of the FDA submissions and regulatory decisions in urology from July 2025.

A key diagnostic clue is that individuals with disordered eating often have unusually precise awareness of their food and fluid intake.

Beyond clinical metrics, Pezzella praised the device’s user-friendly, sophisticated design.

Aleece Fosnight, MSPAS, PA-C, CSC-S, CSE, IF, MSCP, HAES, discusses the strong connection between eating disorders and urinary incontinence in women.

Andrea Pezzella, MD, URPS, FACOG, stressed the need for offering patients comprehensive information on all available therapies.

Clean intermittent catheterization emerged as the second most commonly used bladder management method over time in both sexes.

The SOPHIA2 trial will assess the safety and efficacy of the UroActive implant in men with SUI.

Pezzella said she believes Neuspera offers a "smart, integrated, sophisticated alternative" for treating overactive bladder symptoms.

Among the content is additional information on types of urinary incontinence, ways to control urgency, and frequently asked questions about a healthy bladder.

Colin M. Goudelocke, MD, discusses the PEER trials, which are assessing the safety and efficacy of SNM lead sensing for optimizing SNM programming.

Benjamin M. Brucker, MD, outlines considerations surrounding pre-procedure urinalysis, prophylactic periprocedural antibiotics, and optimal dosing regimens for onabotA administration.

Take a look through all the regulatory milestones in urology from the first half of the 2025.

Here’s a look back at notable news between April and June 2025.

A recap of the FDA submissions and regulatory decisions in urology from June 2025.

The findings strongly support a proactive approach to identifying and referring patients with poor urinary function after RP.

Treatment with the Revi System led to durable QOL benefits at 24 months, even among those patients who did not achieve the primary end point.

Howard B. Goldman, MD, FACS, discusses innovations such as tibial nerve stimulation devices, pudendal nerve targeting, and alternative stimulation frequencies.

Amir S. Patel, MD, discusses interim findings from a randomized controlled trial of onabotulinumtoxinA injection at the time of HoLEP vs standard treatment.

The investigators found a clear, dose-response relationship between patient-reported incontinence severity and the subsequent use of incontinence interventions such as artificial sphincters or bulking agents.

The approval is supported by landmark results from the pivotal phase 2 SANS-UUI trial.

Benjamin M. Brucker, MD, discusses best practices for the onabotulinumtoxinA procedure, spanning all phases of treatment—before, during, and after administration.

The CELLEBRATE trial is aiming to provide additional evidence to support the safety and efficacy of iltamiocel.

Nearly 60% of patients taking vibegron remained on treatment at 1 year.

Yōni.Fit bladder support was granted FDA 510(k) clearance in May 2024.